![]() ![]() |
2nd International AIDS Society Conference on HIV Pathogenesis and TreatmentParis, France - July 13 - 16, 2003 |
IAS Conf HIV Pathog Treat 2003 Jul 13-16;2nd: Abstract No. 70
Antiviral Therapy 2003; 8(Suppl. 1):S202
[ABSTRACT:] Objective: To design strategies for purging latent reservoirs of human immunodeficiency virus type 1 (HIV-1), we investigated mechanisms by which a non-tumour-promoting phorbol ester, prostratin, inhibits infection of CD4 T lymphocytes and in parallel reactivates viral latency.
Design and Methods: CD4 T lymphocytes from primary blood mononuclear cells (PBMC) or in lymphoid tissue stimulated with prostratin were infected with HIV-1 to investigate the effects of prostratin on cellular susceptibility to the virus. Capacity of prostratin to reactivate HIV latency was tested in CD4 T cells harbouring pre-integrated and integrated latent proviruses.
Results: Our results show that prostratin stimulated CD4 T cells in PBMC and lymphoid tissue in an aberrant way. It induced expression of activation markers CD25 and CD69 but inhibited cell cycling. HIV-1 uptake was reduced in prostratin-stimulated CD4 T cells consistently with down-modulation of CD4 and CXCR4 receptors in PBMC and lymphoid tissue. At postentry level, prostratin reduced completion of reverse transcription of the viral genome in lymphatic tissue. Prostratin reactivated HIV-1 from pre- and post-integration latency in resting CD4+ T cells in PBMC and lymphatic tissue.
Conclusions: While prostratin stimulation restricts susceptibility of primary resting CD4 T cells to HIV at the virus cellentry and the reverse transcription levels, it efficiently reactivates expression of pre-integrated and integrated latent HIV-1. This dual role makes of prostratin an excellent candidate for the elimination of persistent HIV infection from latent reservoirs in HAART-treated patients.
030714
70
Copyright © 2003 - International AIDS Society (IAS) and International Medical Press (IMP). Reproduction courtesy of International Medical Press.